<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02802592</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00050961</org_study_id>
    <nct_id>NCT02802592</nct_id>
  </id_info>
  <brief_title>EPOgen and Restrictive Transfusions in Patients Undergoing Cardiac Surgery (EPORT)</brief_title>
  <acronym>EPORT</acronym>
  <official_title>EPOgen and Restrictive Transfusions in Patients Undergoing Cardiac Surgery (EPORT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      EPOgen and Restrictive Transfusions in Patients Undergoing Cardiac Surgery (EPORT)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigator proposes a study investigating the use of restrictive transfusion triggers
      and administration of single preoperative high dose shot of epoetin alfa (rhEPO) in a young
      (age &lt; 65 years of age) population undergoing cardiac surgery. The investigator believes that
      participants can tolerate a lower Hemoglobin (Hgb). Therefore, the control group will benefit
      from a restrictive transfusion trigger and experimental group will benefit from EPO providing
      a synergistic stimulus for erythropoiesis. This proposed study has potential to reduce
      overall transfusion utilization in cardiac surgery and improve standard of care.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Loss of funding
  </why_stopped>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">February 27, 2017</completion_date>
  <primary_completion_date type="Actual">June 15, 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Number of Packed Red Blood Cells Transfused During the Intraoperative and Immediate Postoperative Period</measure>
    <time_frame>Start of surgery to 96 hours post op</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of Stay (# of Total Days Hospitalized)</measure>
    <time_frame>up to one year from date of surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Hospitalization Cost</measure>
    <time_frame>up to one year from date of surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life as Assessed by Short Form-36 Quality of Life Survey</measure>
    <time_frame>assessed at 1-week, 1-month, and 3-months from date of surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Cardiac Surgery-CABG and/or Cardiac Valve Replacement</condition>
  <arm_group>
    <arm_group_label>Epogen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1000 IU/kg Epogen in 250 ml of normal saline infused over 1 hr</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>250 ml normal saline infused over 1 hr</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epogen</intervention_name>
    <description>1:1 randomization to either the Epogen arm or Placebo(Normal Saline) arm</description>
    <arm_group_label>Epogen</arm_group_label>
    <other_name>EPOETIN</other_name>
    <other_name>Procrit</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>1:1 randomization to either the Epogen arm or Placebo(Normal Saline) arm</description>
    <arm_group_label>Normal Saline</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be male or female and 18 years of age or older, but less than 65 years of age

          -  Be willing to performed written informed consent prior to study initiation

          -  Be willing and able to comply with the protocol for study duration

          -  Be scheduled to undergo elective cardiac surgery requiring CPB and including: coronary
             artery bypass graft (CABG), aortic, mitral, or tricuspid valve replacement or repair,
             replacement of more than one cardiac valve, or CABG with combined cardiac valve
             replacement or repair.

        Exclusion Criteria:

          -  Over the age of 64 years

          -  Patients who receive allogeneic transfusion 60 days prior to surgery

          -  Hgb &gt; 15g/dl

          -  Patients who are pregnant or currently lactating

          -  Women of childbearing potential (e.g. those not surgically sterilized or not
             post-menopausal) must use 2 methods of contraception including at least one barrier
             method.

          -  End-stage renal disease requiring renal replacement therapy or dialysis

          -  Hepatic dysfunction (defined as total bilirubin value &gt; 1.5 mg/dl)

          -  Off-pump (no CPB) cardiac surgery

          -  Emergency surgical procedure

          -  Inability to receive blood products

          -  Endocarditis as defined my Modified Duke Criteria

          -  Any congenital coagulation disorder

          -  Chronic anemia (defined as preoperative Hgb concentration &lt; 10 g/dl)

          -  Low platelet count (defined as preoperative platelet count less than 150 x 103/Î¼l)

          -  Not a surgical candidate due to high risk of morbidity or mortality

          -  Surgery for aneurysm repair, dissection, or other thoracic aortic procedure

          -  Congenital heart surgery

          -  Cardiogenic shock or hemodynamic instability within 24 hours prior to surgery, as
             defined by systolic blood pressure &lt; 80 mmHg and heart rate &gt; 120 beats per minute

          -  Known malignancy within the past 5 years

          -  Life expectancy &lt; 12 months

          -  Current active infection requiring antibiotic treatment

          -  Inability to comply with study protocol

          -  Contraindication to Epogen

          -  Hypersensitivity to epoetin or any component of the formulation

          -  Pure red cell aplasia (due to epoetin or other epoetin protein drugs)

          -  Contraindication to Ferrous Sulfate

          -  Hypersensitivity to iron salts or any component of the formulation

          -  Hemochromatosis

          -  Hemolytic anemia

          -  In the opinion of the Principle Investigator (PI) any specific disease process or
             confounding variables that may inappropriately alter the outcome of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keith A. Horvath, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins Community Physicians</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Suburban Hospital</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2016</study_first_submitted>
  <study_first_submitted_qc>June 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2016</study_first_posted>
  <results_first_submitted>August 17, 2017</results_first_submitted>
  <results_first_submitted_qc>August 17, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 14, 2017</results_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This study was terminated due to loss of funding and those participants enrolled were not un-blinded to the study team members.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>All Participants</title>
          <description>1000 IU/kg Epogen in 250 ml of normal saline infused over 1 hr Epogen: 1:1 randomization to either the Epogen arm or Placebo(Normal Saline) arm
OR
250 ml normal saline infused over 1 hr Normal Saline: 1:1 randomization to either the Epogen arm or Placebo(Normal Saline) arm</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study terminated due to loss of funding</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This study was terminated due to loss of funding and those participants enrolled were not un-blinded to the study team members.</population>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>1000 IU/kg Epogen in 250 ml of normal saline infused over 1 hr Epogen: 1:1 randomization to either the Epogen arm or Placebo(Normal Saline) arm
OR
250 ml normal saline infused over 1 hr Normal Saline: 1:1 randomization to either the Epogen arm or Placebo(Normal Saline) arm</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Number of Packed Red Blood Cells Transfused During the Intraoperative and Immediate Postoperative Period</title>
        <time_frame>Start of surgery to 96 hours post op</time_frame>
        <population>This study was terminated prematurely due to a loss of funding. There is no data available for this outcome measure as any data collected was not unblinded to the study team nor was it analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Epogen</title>
            <description>1000 IU/kg Epogen in 250 ml of normal saline infused over 1 hr
Epogen: 1:1 randomization to either the Epogen arm or Placebo(Normal Saline) arm</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>250 ml normal saline infused over 1 hr
Normal Saline: 1:1 randomization to either the Epogen arm or Placebo(Normal Saline) arm</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Packed Red Blood Cells Transfused During the Intraoperative and Immediate Postoperative Period</title>
          <population>This study was terminated prematurely due to a loss of funding. There is no data available for this outcome measure as any data collected was not unblinded to the study team nor was it analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Stay (# of Total Days Hospitalized)</title>
        <time_frame>up to one year from date of surgery</time_frame>
        <population>This study was terminated prematurely due to a loss of funding. There is no data available for this outcome measure as any data collected was not unblinded to the study team nor was it analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Epogen</title>
            <description>1000 IU/kg Epogen in 250 ml of normal saline infused over 1 hr
Epogen: 1:1 randomization to either the Epogen arm or Placebo(Normal Saline) arm</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>250 ml normal saline infused over 1 hr
Normal Saline: 1:1 randomization to either the Epogen arm or Placebo(Normal Saline) arm</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Stay (# of Total Days Hospitalized)</title>
          <population>This study was terminated prematurely due to a loss of funding. There is no data available for this outcome measure as any data collected was not unblinded to the study team nor was it analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Hospitalization Cost</title>
        <time_frame>up to one year from date of surgery</time_frame>
        <population>This study was terminated prematurely due to a loss of funding. There is no data available for this outcome measure as any data collected was not unblinded to the study team nor was it analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Epogen</title>
            <description>1000 IU/kg Epogen in 250 ml of normal saline infused over 1 hr
Epogen: 1:1 randomization to either the Epogen arm or Placebo(Normal Saline) arm</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>250 ml normal saline infused over 1 hr
Normal Saline: 1:1 randomization to either the Epogen arm or Placebo(Normal Saline) arm</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Hospitalization Cost</title>
          <population>This study was terminated prematurely due to a loss of funding. There is no data available for this outcome measure as any data collected was not unblinded to the study team nor was it analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life as Assessed by Short Form-36 Quality of Life Survey</title>
        <time_frame>assessed at 1-week, 1-month, and 3-months from date of surgery</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>All Participants</title>
          <description>1000 IU/kg Epogen in 250 ml of normal saline infused over 1 hr Epogen: 1:1 randomization to either the Epogen arm or Placebo(Normal Saline) arm
OR
250 ml normal saline infused over 1 hr Normal Saline: 1:1 randomization to either the Epogen arm or Placebo(Normal Saline) arm</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Mediastinal bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Ankle Edema (Bilateral)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Complete Heart Block</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Acute Congestive Heart Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Kenneth Horvath</name_or_title>
      <organization>Johns Hopkins University School of Medicine</organization>
      <phone>301-896-3100</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

